17 May 2022 | News
'Skytypoid', a protein-conjugated typhoid vaccine with differentiated competitiveness, has proven equivalent immunogenicity compared to WHO-approved vaccines
Image credit: shutterstock
South Korea-based SK Bioscience has secured another approval for in-house vaccine.
SK Bioscience obtained an export license for the typhoid vaccine 'Skytyphoid Multi-Zoo (task name NBP618, hereafter referred to as Skytyphoid)' jointly developed with IVI (International Vaccine Institute) for domestic food and drug safety.
Skytyphoid is a typhoid vaccine developed by SK Bioscience and IVI in 2013 by applying conjugate vaccine production technology. From the initial stage of R&D, the Bill & Melinda Gates Foundation supported research funds, SK Bioscience was in charge of R&D, production and licensing, and IVI was in charge of global clinical trials.
Skytypoid is a polysaccharide-protein conjugate vaccine developed by conjugating the polysaccharide of typhoid bacteria, which acts as an antigen, to the diphtheria toxin protein (diphtheria toxoid), which acts as a carrier.
SK Bioscience plans to quickly enter the WHO (World Health Organization) PQ (Pre-Qualification) certification process based on excellent clinical results and product approval from the Ministry of Food and Drug Safety. SK Bioscience aims to obtain WHO PQ certification in cooperation with IVI, and to supply Skytypoid globally as early as next year. SK Bioscience's vaccine plant, Andong L House, will be in charge of both production and supply of Skytypoid.